JCI - Citations to Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs

Citations to this article

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs

Herbert Y. Meltzer, Bryan L. Roth

Herbert Y. Meltzer, Bryan L. Roth

Published December 2, 2013
Citation Information: J Clin Invest. 2013;123(12):4986-4991. https://doi.org/10.1172/JCI70678.

View: Text | PDF

Total citations by year

Year:	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2009	Total
Citations:	1	1	9	5	4	3	3	3	7	6	8	1	1	52

Citation information

Citations to this article (52)

Title and authors	Publication	Year
Construction and application of magnetic surface molecularly imprinted solid-phase extraction for the detection of 5-hydroxytryptamine in peripheral blood. Zhu G, Li X, Ma Q, Hong Z, Zhong D, Sun X	Mikrochimica acta	2025
5-Methoxy-2-aminoindane Reverses Diet-Induced Obesity and Improves Metabolic Parameters in Mice: A Potential New Class of Antiobesity Therapeutics Baraghithy S, Gammal A, Permyakova A, Hamad S, Kočvarová R, Calles Y, Tam J		2024
The G protein biased serotonin 5-HT 2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice Pogorelov VM, Rodriguiz RM, Roth BL, Wetsel WC		2023
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity Pati B, Sendh S, Sahu B, Pani S, Jena N, Bal NC		2023
Molecular Docking Assessment of Cathinones as 5-HT2AR Ligands: Developing of Predictive Structure-Based Bioactive Conformations and Three-Dimensional Structure-Activity Relationships Models for Future Recognition of Abuse Drugs Tomašević N, Vujović M, Kostić E, Ragavendran V, Arsić B, Matić SL, Božović M, Fioravanti R, Proia E, Ragno R, Mladenović M	Molecules (Basel, Switzerland)	2023
End of life care of hospitalized patients with Parkinson disease: a retrospective analysis and brief review Bhansali S, Assaedi E, Yu JR, Mandava N, Sonneborn C, Hogue O, Walter BL, Samala RV, Margolius A	Frontiers in aging neuroscience	2023
Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis Li HY, Huang SY, Zhou DD, Xiong RG, Luo M, Saimaiti A, Han MK, Gan RY, Zhu HL, Li HB	Journal of Advanced Research	2023
A suite of engineered mice for interrogating psychedelic drug actions Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD, Llorach P, Bowyer K, Liu B, Sciaky N, Hua K, Chen C, Mott SE, Niehaus J, DiBerto JF, English J, Walsh JJ, Scherrer G, Herman MA, Wu Z, Wetsel WC, Roth BL		2023
The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice. Pogorelov VM, Rodriguiz RM, Roth BL, Wetsel WC	Frontiers in Molecular Biosciences	2023
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes Lisco G, De Tullio A, Iovino M, Disoteo O, Guastamacchia E, Giagulli VA, Triggiani V	Biomedicines	2023
Serotonin/5‐HT7 receptor provides an adaptive signal to enhance pigmentation response to environmental stressors through cAMP‐PKA‐MAPK, Rab27a/RhoA, and PI3K/AKT signaling pathways Tang H, Zhang Y, Yang L, Hong C, Chen K, Li Y, Wu H	The FASEB Journal	2023
Migraine signaling pathways: amino acid metabolites that regulate migraine and predispose migraineurs to headache R Biringer	Molecular and Cellular Biochemistry	2022
Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity Huang J, Pham M, Panenka WJ, Honer WG, Barr AM	Frontiers in Psychiatry	2022
Impact of specific serotonin receptor modulation on restricted repetitive behaviors Alvarez BD, Cavazos C, Morales CA, M. Lopez S, Amodeo DA	Frontiers in behavioral neuroscience	2022
Bespoke library docking for 5-HT2A receptor agonists with anti-depressant activity Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy J, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA	Nature	2022
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment. Bugarski-Kirola D, Bitter I, Liu IY, Abbs B, Stankovic S		2022
Impact of specific serotonin receptor modulation on behavioral flexibility BD Alvarez, CA Morales, DA Amodeo	Pharmacology, biochemistry, and behavior	2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? YJ Tak, SY Lee	Current Obesity Reports	2021
Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date V Soogrim, VL Ruberto, J Murrough, MK Jha	Drug design, development and therapy	2021
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review YJ Tak, SY Lee	The World Journal of Men's Health	2021
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function NM Barnes, GP Ahern, C Becamel, J Bockaert, M Camilleri, S Chaumont-Dubel, S Claeysen, KA Cunningham, KC Fone, M Gershon, GD Giovanni, NM Goodfellow, AL Halberstadt, RM Hartley, G Hassaine, K Herrick-Davis, R Hovius, E Lacivita, EK Lambe, M Leopoldo, FO Levy, SC Lummis, P Marin, L Maroteaux, AC McCreary, DL Nelson, JF Neumaier, A Newman-Tancredi, H Nury, A Roberts, BL Roth, A Roumier, GJ Sanger, M Teitler, T Sharp, CM Villalón, H Vogel, SW Watts, D Hoyer, EH Ohlstein	Pharmacological reviews	2020
A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts B Zhang, S Zhao, D Yang, Y Wu, Y Xin, H Cao, , X Cai, W Sun, N Ye, Y Xu, Y Peng, S Zhao, ZJ Liu, G Zhong, MW Wang, W Shui	ACS Central Science	2020
Serotonin/5-HT1A Signaling in the Neurovascular Unit Regulates Endothelial CLDN5 Expression K Sugimoto, N Ichikawa-Tomikawa, K Nishiura, Y Kunii, Y Sano, F Shimizu, A Kakita, T Kanda, T Imura, H Chiba	International journal of molecular sciences	2020
Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146 A Leiherer, A Muendlein, CH Saely, P Fraunberger, H Drexel	Scientific Reports	2019
Identification of fluorinated (R)-(−)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor Y Xu, AW Sromek, JL Neumeyer	Bioorganic & Medicinal Chemistry Letters	2019
Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review RS Patel, J Bhela, M Tahir, SR Pisati, S Hossain	Cureus	2019
5-HT 2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology Y Peng, JD McCorvy, K Harpsøe, K Lansu, S Yuan, P Popov, L Qu, M Pu, T Che, LF Nikolajsen, XP Huang, Y Wu, L Shen, WE Bjørn-Yoshimoto, K Ding, D Wacker, GW Han, J Cheng, V Katritch, AA Jensen, MA Hanson, S Zhao, DE Gloriam, BL Roth, RC Stevens, ZJ Liu	Cell	2018
Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity KA Berg, WP Clarke	The International Journal of Neuropsychopharmacology	2018
Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder D Firouzabadi, N Firouzabadi, K Kalani, K Zomorrodian, ES Tehrani	European Journal of Clinical Pharmacology	2018
The Atypical Antipsychotic Olanzapine Targets Htr2c to Cause Weight Gain Caleb Lord, Steven Wyler, Rong Wan, Carlos Castorena, Newaz Ahmed, Dias Mathew, Syann Lee, Chen Liu, Joel K. Elmquist	Journal of Clinical Investigation	2017
Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome A Griffin, KR Hamling, K Knupp, SG Hong, LP Lee, SC Baraban	Brain	2017
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction SJ Shah	Journal of Cardiovascular Translational Research	2017
Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms X Huang, J Yang, S Yang, S Cao, D Qin, Y Zhou, X Li, Y Ye, J Wu	Oncotarget	2017
Effects of lorcaserin (Belviq®) on nicotine- and food-maintained responding in non-human primates DS Jacobs, CE Barkin, MR Kohut, J Bergman, SJ Kohut	Drug and Alcohol Dependence	2017
Identification of Optically Active Pyrimidine Derivatives as Selective 5-HT2C Modulators J Kim, H Jo, H Lee, H Choo, H Kim, A Pae, Y Cho, SJ Min	Molecules (Basel, Switzerland)	2017
Discovery of N -Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications G Zhang, J Cheng, JD McCorvy, PJ Lorello, BJ Caldarone, BL Roth, AP Kozikowski	Journal of Medicinal Chemistry	2017
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models J Cheng, PM Giguere, CM Schmerberg, VM Pogorelov, RM Rodriguiz, XP Huang, H Zhu, JD McCorvy, WC Wetsel, BL Roth, AP Kozikowski	Journal of Medicinal Chemistry	2016
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine MS Farrell, JD McCorvy, XP Huang, DJ Urban, KL White, PM Giguere, AK Doak, AI Bernstein, KA Stout, SM Park, RM Rodriguiz, BW Gray, WS Hyatt, AP Norwood, KA Webster, BM Gannon, GW Miller, JH Porter, BK Shoichet, WE Fantegrossi, WC Wetsel, BL Roth, H Zhou	PloS one	2016
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases GD Giovanni, DS Strac, M Sole, M Unzeta, KF Tipton, D Mück-Šeler, I Bolea, LD Corte, MN Perkovic, N Pivac, IJ Smolders, A Stasiak, WA Fogel, PD Deurwaerdère	Frontiers in neuroscience	2016
A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, A Karlsson, B Al-Lazikani, A Hersey, TI Oprea, JP Overington	Nature Reviews Drug Discovery	2016
Activation of Ventral Tegmental Area 5-HT2C Receptors Reduces Incentive Motivation L Valencia-Torres, CM Olarte-Sánchez, DJ Lyons, T Georgescu, M Greenwald-Yarnell, MG Myers, CM Bradshaw, LK Heisler	Neuropsychopharmacology	2016
Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis H Sarva, C Henchcliffe	Therapeutic advances in neurological disorders	2016
Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents J Cheng, PM Giguère, OK Onajole, W Lv, A Gaisin, H Gunosewoyo, CM Schmerberg, VM Pogorelov, RM Rodriguiz, G Vistoli, WC Wetsel, BL Roth, AP Kozikowski	Journal of Medicinal Chemistry	2015
Design and synthesis of (2-(5-chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a selective serotonin 2C agonist J Cheng, PM Giguere, W Lv, BL Roth, AP Kozikowski	Tetrahedron Letters	2015
Structure and function of serotonin G protein-coupled receptors JD McCorvy, BL Roth	Pharmacology & Therapeutics	2015
Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex C Nocjar, KD Alex, A Sonneborn, AI Abbas, BL Roth, EA Pehek	Neuroscience	2015
Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily BL Roth, WK Kroeze	The Journal of biological chemistry	2015
Development of the 5-HT2CR-Tango System Combined with an EGFP Reporter Gene Y Watanabe, A Tsujimura, M Aoki, K Taguchi, M Tanaka	Journal of Molecular Neuroscience	2015
The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour S Higgs, AJ Cooper, NM Barnes	Psychopharmacology	2015
We Need 2C but Not 2B: Developing Serotonin 2C (5-HT 2C ) Receptor Agonists for the Treatment of CNS Disorders J Cheng, AP Kozikowski	ChemMedChem	2015
DREADD: A Chemogenetic GPCR Signaling Platform H Zhu, BL Roth	The International Journal of Neuropsychopharmacology	2014
Pulmonary surfactant: an immunological perspective ZC Chroneos, Z Sever-Chroneos, VL Shepherd	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2009

Advertisement